ArticleTissue engineering and regenerative medicine2026
A Pilot Study for Establishing DSS-Induced Colitis Model in Minipigs.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing and remitting colonic mucosal inflammation. Rodent dextran sodium sulfate (DSS) induced colitis models are widely used but have limited translational relevance due to anatomical and physiological differences. As a pilot feasibility study, this work aimed to explore whether graded DSS administration could induce reproducible colitis-like features in minipigs.
methodsWe developed a pilot large-animal UC model using Sus scrofa minipigs. Eight male Micropigs® were divided into four groups, with three groups receiving DSS at 0.2, 0.4, or 0.8 g/kg/day for 7 days. Clinical signs, body weight, colon length, endoscopic evaluation, and histopathology were assessed.
resultsDSS administration induced dose-dependent UC features. Group 4 minipigs (0.8 g/kg/day) showed the most severe clinical manifestations, including diarrhea, anorexia, and lethargy. Colon length was reduced by 34% in Group 4 compared to controls. Endoscopy revealed progressive mucosal edema, hemorrhage, and erosions. Histopathological scoring confirmed severe inflammation, crypt loss, and ulceration in higher-dose groups. Dose-dependent trends were consistently observed across clinical signs, endoscopic findings, and histopathological features.
conclusionThis DSS-induced minipig colitis model replicates clinical, endoscopic, and histological hallmarks of human UC. As an exploratory pilot study, it provides proof-of-concept for minipigs as a translational platform for inflammatory bowel disease (IBD) research and therapeutic evaluation.
Indexed as
Identifiers
42573889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.